CD8 T-cell expansions in HIV patients, treated with HAART, who have long-term suppression of HIV-RNA

Completed

• Conditions: AIDS; Seropositive; 10047438

• Registration Number: NL-OMON32924
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 12 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

-All study subjects have to be adults (18 years of age, or older) and of sound mind and judgement.
-They have to be infected with HIV-1 and treated with HAART for at least 5 years.
-They have to have a long-term undetectable viral load (=HIV-RNA < 50 copies/ml).
-The number of CD4 T-cells should have increased to at least 500 cells per microliter blood.
-They have to be HLA-A2 or HLA-B8 positive.

Exclusion Criteria

-Participants may not have had a flu, cold or any other infection at least two weeks prior to blood donation.
-They may not have an active hepatitis B or C infection.
-They may not use immune suppressive or immune modulating medication.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>-The percentage of CD8 T-cells that is apoptosis-resistant, compared to<br /><br>healthy, age matched, controls. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-The percentage of CD8 T-cells that shows an exhausted phenotype, compared to<br /><br>healthy controls.<br /><br>-The copie number of HIV-1 RNA in plasma, with a test that can detect numbers<br /><br>as low as 5 copies per ml plasma.<br /><br>-The percentage of CD8 T-cells that is specific for CMV or EBV.<br /><br>-The TREC numbers in all subpopulations of the CD8 T-cell compartment (naive,<br /><br>memory and effector cells).</p><br>